There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.
Jan 25, 2021
0
39
Leptin is an adipocyte-derived hormone that stimulates hypothalamic neurons to strongly inhibit food intake. Leptin signaling in the hypothalamus, a part of the mid-brain, thus plays a crucial role in the regulation of body ...
Sep 15, 2017
0
3
A research team led by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia ...
Jun 3, 2013
0
0
Some cancer drugs used to treat patients with leukemia may also help stop the Ebola virus and give the body time to control the infection before it turns deadly, US researchers said on Wednesday.
Feb 29, 2012
0
0
New research published in BioMed Central's open access journal Cell Communication and Signaling describes a large set of interactions (interactome) which maps the range of phosphotyrosine (pTyr)-dependent interactions with ...
Sep 13, 2012
0
0
Patients suffering from hereditary neuropathy may have hope for new treatment thanks to a Geisinger study that uncovered a key to the development of the peripheral nervous system.
May 29, 2013
0
1
Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published today ...
Jul 19, 2013
0
0
Approximately 68 percent of U.S. adults are overweight or obese, according to the National Cancer Institute, which puts them at greater risk for developing cancer, cardiovascular disease, diabetes and a host of other chronic ...
Dec 5, 2012
0
0
Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients ...
Dec 12, 2012
0
0
Huntsman Cancer Institute (HCI) researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard ...
Nov 30, 2012
0
0
